Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Toxic high-dose chemotherapy may not be necessary to cure Burkitt's lymphoma in adults and patients with immunodeficiency. An infusion-based chemotherapy program with modest toxicity administered mainly in outpatients resulted in an overall survival rate of 90 to 100%. Burkitt's lymphoma,...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2013-11, Vol.369 (20), p.1915-1925 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1925 |
|---|---|
| container_issue | 20 |
| container_start_page | 1915 |
| container_title | The New England journal of medicine |
| container_volume | 369 |
| creator | Dunleavy, Kieron Pittaluga, Stefania Shovlin, Margaret Steinberg, Seth M Cole, Diane Grant, Cliona Widemann, Brigitte Staudt, Louis M Jaffe, Elaine S Little, Richard F Wilson, Wyndham H |
| description | Toxic high-dose chemotherapy may not be necessary to cure Burkitt's lymphoma in adults and patients with immunodeficiency. An infusion-based chemotherapy program with modest toxicity administered mainly in outpatients resulted in an overall survival rate of 90 to 100%.
Burkitt's lymphoma, first described by Denis Burkitt in African children, is a highly proliferative human cancer.
1
Although rare, Burkitt's lymphoma disproportionately affects children, accounting for 30 to 50% of pediatric lymphomas. Three major variants are recognized: endemic, which occurs in equatorial Africa; sporadic, which occurs worldwide; and immunodeficiency-associated, which occurs primarily in persons with human immunodeficiency virus (HIV) infection. Young patients with sporadic Burkitt's lymphoma have a favorable outcome with intense short-cycle treatment, whereas adult patients and those with immunodeficiency have inferior outcomes.
2
–
7
Burkitt's lymphoma is derived from a germinal-center B cell and has distinct oncogenic pathways.
8
,
9
A . . . |
| doi_str_mv | 10.1056/NEJMoa1308392 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3901044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3127373341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-ccf0a8f0a2224028d2065063c69cb489f500f51251f372119c645b4711eb96453</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMotlaXbmVAxNVonjOTjVBL1UrVTV2HTJqxU-dlkrHMvzfSWu3CC5cbyMc5hwPAKYJXCLLo-nn8-FRLRGBCON4DfcQICSmF0T7oQ4iTkMac9MCRtUvoB1F-CHqYYkwjTPsgntarcFI5XdncdcFsoY1suiCvguG8LZwNVrlbBLetec-du7TBtCubRV3KY3CQycLqk80dgNe78Wz0EE5f7iej4TRUNGYuVCqDMvGLvaFPM8cwYjAiKuIqpQnPGIQZQ5ihjMQYIa4iylIaI6RT7p9kAG7Wuk2blnqudOWMLERj8lKaTtQyF7s_Vb4Qb_WnIBwiSKkXON8ImPqj1daJZd2aymcWiLKEcR7HkafCNaVMba3R2dYBQfHds9jp2fNnf2Nt6Z9iPXCxAaRVssiMrFRuf7mYI0r8bLmytKLSy_Ifwy9BSI84</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458599776</pqid></control><display><type>article</type><title>Low-Intensity Therapy in Adults with Burkitt's Lymphoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Dunleavy, Kieron ; Pittaluga, Stefania ; Shovlin, Margaret ; Steinberg, Seth M ; Cole, Diane ; Grant, Cliona ; Widemann, Brigitte ; Staudt, Louis M ; Jaffe, Elaine S ; Little, Richard F ; Wilson, Wyndham H</creator><creatorcontrib>Dunleavy, Kieron ; Pittaluga, Stefania ; Shovlin, Margaret ; Steinberg, Seth M ; Cole, Diane ; Grant, Cliona ; Widemann, Brigitte ; Staudt, Louis M ; Jaffe, Elaine S ; Little, Richard F ; Wilson, Wyndham H</creatorcontrib><description>Toxic high-dose chemotherapy may not be necessary to cure Burkitt's lymphoma in adults and patients with immunodeficiency. An infusion-based chemotherapy program with modest toxicity administered mainly in outpatients resulted in an overall survival rate of 90 to 100%.
Burkitt's lymphoma, first described by Denis Burkitt in African children, is a highly proliferative human cancer.
1
Although rare, Burkitt's lymphoma disproportionately affects children, accounting for 30 to 50% of pediatric lymphomas. Three major variants are recognized: endemic, which occurs in equatorial Africa; sporadic, which occurs worldwide; and immunodeficiency-associated, which occurs primarily in persons with human immunodeficiency virus (HIV) infection. Young patients with sporadic Burkitt's lymphoma have a favorable outcome with intense short-cycle treatment, whereas adult patients and those with immunodeficiency have inferior outcomes.
2
–
7
Burkitt's lymphoma is derived from a germinal-center B cell and has distinct oncogenic pathways.
8
,
9
A . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1308392</identifier><identifier>PMID: 24224624</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject><![CDATA[Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; B-cell lymphoma ; Biological and medical sciences ; Burkitt Lymphoma - complications ; Burkitt Lymphoma - drug therapy ; Burkitt's lymphoma ; Cancer therapies ; Chemotherapy ; Children ; Cyclin-dependent kinases ; Cyclophosphamide ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Drug dosages ; Etoposide ; Etoposide - administration & dosage ; Etoposide - adverse effects ; Female ; Fever ; Fluids ; General aspects ; Hematologic and hematopoietic diseases ; HIV ; HIV Seropositivity - complications ; Human immunodeficiency virus ; Humans ; Immunocompromised Host ; Infectious diseases ; Laboratories ; Leukemia ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphocytes B ; Lymphoma ; Lysis ; Male ; Medical sciences ; Middle Aged ; Monoclonal antibodies ; Nervous system ; Neurological disorders ; Neutropenia ; Neutrophils ; Patients ; Pediatrics ; Prednisone ; Prednisone - administration & dosage ; Prednisone - adverse effects ; Prospective Studies ; Rituximab ; Targeted cancer therapy ; Vincristine ; Vincristine - administration & dosage ; Vincristine - adverse effects ; Viral diseases]]></subject><ispartof>The New England journal of medicine, 2013-11, Vol.369 (20), p.1915-1925</ispartof><rights>Copyright © 2013 Massachusetts Medical Society. All rights reserved.</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 Massachusetts Medical Society. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-ccf0a8f0a2224028d2065063c69cb489f500f51251f372119c645b4711eb96453</citedby><cites>FETCH-LOGICAL-c475t-ccf0a8f0a2224028d2065063c69cb489f500f51251f372119c645b4711eb96453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1308392$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1308392$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26082,27903,27904,52360,54042</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27914333$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24224624$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dunleavy, Kieron</creatorcontrib><creatorcontrib>Pittaluga, Stefania</creatorcontrib><creatorcontrib>Shovlin, Margaret</creatorcontrib><creatorcontrib>Steinberg, Seth M</creatorcontrib><creatorcontrib>Cole, Diane</creatorcontrib><creatorcontrib>Grant, Cliona</creatorcontrib><creatorcontrib>Widemann, Brigitte</creatorcontrib><creatorcontrib>Staudt, Louis M</creatorcontrib><creatorcontrib>Jaffe, Elaine S</creatorcontrib><creatorcontrib>Little, Richard F</creatorcontrib><creatorcontrib>Wilson, Wyndham H</creatorcontrib><title>Low-Intensity Therapy in Adults with Burkitt's Lymphoma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Toxic high-dose chemotherapy may not be necessary to cure Burkitt's lymphoma in adults and patients with immunodeficiency. An infusion-based chemotherapy program with modest toxicity administered mainly in outpatients resulted in an overall survival rate of 90 to 100%.
Burkitt's lymphoma, first described by Denis Burkitt in African children, is a highly proliferative human cancer.
1
Although rare, Burkitt's lymphoma disproportionately affects children, accounting for 30 to 50% of pediatric lymphomas. Three major variants are recognized: endemic, which occurs in equatorial Africa; sporadic, which occurs worldwide; and immunodeficiency-associated, which occurs primarily in persons with human immunodeficiency virus (HIV) infection. Young patients with sporadic Burkitt's lymphoma have a favorable outcome with intense short-cycle treatment, whereas adult patients and those with immunodeficiency have inferior outcomes.
2
–
7
Burkitt's lymphoma is derived from a germinal-center B cell and has distinct oncogenic pathways.
8
,
9
A . . .</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>B-cell lymphoma</subject><subject>Biological and medical sciences</subject><subject>Burkitt Lymphoma - complications</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Burkitt's lymphoma</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Children</subject><subject>Cyclin-dependent kinases</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Drug dosages</subject><subject>Etoposide</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - adverse effects</subject><subject>Female</subject><subject>Fever</subject><subject>Fluids</subject><subject>General aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>HIV</subject><subject>HIV Seropositivity - complications</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Nervous system</subject><subject>Neurological disorders</subject><subject>Neutropenia</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prednisone</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - adverse effects</subject><subject>Prospective Studies</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><subject>Vincristine</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - adverse effects</subject><subject>Viral diseases</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kEtLAzEUhYMotlaXbmVAxNVonjOTjVBL1UrVTV2HTJqxU-dlkrHMvzfSWu3CC5cbyMc5hwPAKYJXCLLo-nn8-FRLRGBCON4DfcQICSmF0T7oQ4iTkMac9MCRtUvoB1F-CHqYYkwjTPsgntarcFI5XdncdcFsoY1suiCvguG8LZwNVrlbBLetec-du7TBtCubRV3KY3CQycLqk80dgNe78Wz0EE5f7iej4TRUNGYuVCqDMvGLvaFPM8cwYjAiKuIqpQnPGIQZQ5ihjMQYIa4iylIaI6RT7p9kAG7Wuk2blnqudOWMLERj8lKaTtQyF7s_Vb4Qb_WnIBwiSKkXON8ImPqj1daJZd2aymcWiLKEcR7HkafCNaVMba3R2dYBQfHds9jp2fNnf2Nt6Z9iPXCxAaRVssiMrFRuf7mYI0r8bLmytKLSy_Ifwy9BSI84</recordid><startdate>20131114</startdate><enddate>20131114</enddate><creator>Dunleavy, Kieron</creator><creator>Pittaluga, Stefania</creator><creator>Shovlin, Margaret</creator><creator>Steinberg, Seth M</creator><creator>Cole, Diane</creator><creator>Grant, Cliona</creator><creator>Widemann, Brigitte</creator><creator>Staudt, Louis M</creator><creator>Jaffe, Elaine S</creator><creator>Little, Richard F</creator><creator>Wilson, Wyndham H</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20131114</creationdate><title>Low-Intensity Therapy in Adults with Burkitt's Lymphoma</title><author>Dunleavy, Kieron ; Pittaluga, Stefania ; Shovlin, Margaret ; Steinberg, Seth M ; Cole, Diane ; Grant, Cliona ; Widemann, Brigitte ; Staudt, Louis M ; Jaffe, Elaine S ; Little, Richard F ; Wilson, Wyndham H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-ccf0a8f0a2224028d2065063c69cb489f500f51251f372119c645b4711eb96453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>B-cell lymphoma</topic><topic>Biological and medical sciences</topic><topic>Burkitt Lymphoma - complications</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Burkitt's lymphoma</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Children</topic><topic>Cyclin-dependent kinases</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Drug dosages</topic><topic>Etoposide</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - adverse effects</topic><topic>Female</topic><topic>Fever</topic><topic>Fluids</topic><topic>General aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>HIV</topic><topic>HIV Seropositivity - complications</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Nervous system</topic><topic>Neurological disorders</topic><topic>Neutropenia</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prednisone</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - adverse effects</topic><topic>Prospective Studies</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><topic>Vincristine</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - adverse effects</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dunleavy, Kieron</creatorcontrib><creatorcontrib>Pittaluga, Stefania</creatorcontrib><creatorcontrib>Shovlin, Margaret</creatorcontrib><creatorcontrib>Steinberg, Seth M</creatorcontrib><creatorcontrib>Cole, Diane</creatorcontrib><creatorcontrib>Grant, Cliona</creatorcontrib><creatorcontrib>Widemann, Brigitte</creatorcontrib><creatorcontrib>Staudt, Louis M</creatorcontrib><creatorcontrib>Jaffe, Elaine S</creatorcontrib><creatorcontrib>Little, Richard F</creatorcontrib><creatorcontrib>Wilson, Wyndham H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dunleavy, Kieron</au><au>Pittaluga, Stefania</au><au>Shovlin, Margaret</au><au>Steinberg, Seth M</au><au>Cole, Diane</au><au>Grant, Cliona</au><au>Widemann, Brigitte</au><au>Staudt, Louis M</au><au>Jaffe, Elaine S</au><au>Little, Richard F</au><au>Wilson, Wyndham H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-Intensity Therapy in Adults with Burkitt's Lymphoma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2013-11-14</date><risdate>2013</risdate><volume>369</volume><issue>20</issue><spage>1915</spage><epage>1925</epage><pages>1915-1925</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Toxic high-dose chemotherapy may not be necessary to cure Burkitt's lymphoma in adults and patients with immunodeficiency. An infusion-based chemotherapy program with modest toxicity administered mainly in outpatients resulted in an overall survival rate of 90 to 100%.
Burkitt's lymphoma, first described by Denis Burkitt in African children, is a highly proliferative human cancer.
1
Although rare, Burkitt's lymphoma disproportionately affects children, accounting for 30 to 50% of pediatric lymphomas. Three major variants are recognized: endemic, which occurs in equatorial Africa; sporadic, which occurs worldwide; and immunodeficiency-associated, which occurs primarily in persons with human immunodeficiency virus (HIV) infection. Young patients with sporadic Burkitt's lymphoma have a favorable outcome with intense short-cycle treatment, whereas adult patients and those with immunodeficiency have inferior outcomes.
2
–
7
Burkitt's lymphoma is derived from a germinal-center B cell and has distinct oncogenic pathways.
8
,
9
A . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>24224624</pmid><doi>10.1056/NEJMoa1308392</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2013-11, Vol.369 (20), p.1915-1925 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3901044 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects B-cell lymphoma Biological and medical sciences Burkitt Lymphoma - complications Burkitt Lymphoma - drug therapy Burkitt's lymphoma Cancer therapies Chemotherapy Children Cyclin-dependent kinases Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Doxorubicin Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug dosages Etoposide Etoposide - administration & dosage Etoposide - adverse effects Female Fever Fluids General aspects Hematologic and hematopoietic diseases HIV HIV Seropositivity - complications Human immunodeficiency virus Humans Immunocompromised Host Infectious diseases Laboratories Leukemia Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphocytes B Lymphoma Lysis Male Medical sciences Middle Aged Monoclonal antibodies Nervous system Neurological disorders Neutropenia Neutrophils Patients Pediatrics Prednisone Prednisone - administration & dosage Prednisone - adverse effects Prospective Studies Rituximab Targeted cancer therapy Vincristine Vincristine - administration & dosage Vincristine - adverse effects Viral diseases |
| title | Low-Intensity Therapy in Adults with Burkitt's Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A15%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-Intensity%20Therapy%20in%20Adults%20with%20Burkitt's%20Lymphoma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Dunleavy,%20Kieron&rft.date=2013-11-14&rft.volume=369&rft.issue=20&rft.spage=1915&rft.epage=1925&rft.pages=1915-1925&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1308392&rft_dat=%3Cproquest_pubme%3E3127373341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1458599776&rft_id=info:pmid/24224624&rfr_iscdi=true |